Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with the Hemopump.

O H Frazier1, T Nakatani, J M Duncan

  • 1Cullen Cardiovascular Surgical Research Laboratories, Texas Heart Institute, Houston 77225.

ASAIO Transactions
|July 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A conceptual model for dissolved P mobilization from legacy sources.

Journal of environmental quality·2025
Same author

Prioritizing conservation practice locations for effective water quality improvement using the Agricultural Conservation Planning Framework (ACPF) and the Soil and Water Assessment Tool (SWAT).

Journal of environmental management·2023
Same author

A feasibility study into the use of three-dimensional printer modelling in acetabular fracture surgery.

Advances in orthopedics·2015
Same author

On Albuminuria with Parametritis.

Medico-chirurgical transactions·2010
Same author

Hospital versus Home Practice.

British medical journal·2010
Same author

Hospital versus Home Practice.

British medical journal·2010
Same journal

Extracorporeal membrane oxygenation as a means of stabilizing and transporting high risk neonates.

ASAIO transactions·1991
Same journal

Pumping capabilities of the latissimus dorsi and rectus abdominis muscles wrapped around a valved pouch in a mock circulatory system.

ASAIO transactions·1991
Same journal

Causes of intraaortic balloon leaks.

ASAIO transactions·1991
Same journal

Influence of centrifugal blood pumps on the elasticity of erythrocytes.

ASAIO transactions·1991
Same journal

Reuse of "highly permeable" dialyzers with peroxyacetic acid as sole cleansing and disinfecting agent.

ASAIO transactions·1991
Same journal

Comparison of 50% dextrose water, 25% mannitol, and 23.5% saline for the treatment of hemodialysis-associated muscle cramps.

ASAIO transactions·1991
See all related articles

The Hemopump, an intraarterial left ventricular assist device (LVAD), offers safe and effective temporary circulatory support for patients with severe left ventricular failure (LVF). This minimally invasive device was successfully used in 12 patients, with 10 weaned off support and minimal complications.

Area of Science:

  • Cardiovascular Surgery
  • Biomedical Engineering
  • Critical Care Medicine

Background:

  • Surgical implantation of traditional left ventricular assist devices (LVADs) can lead to complications, limiting their use in patients with profound left ventricular failure (LVF).
  • Minimally invasive approaches are needed to overcome the limitations of conventional LVADs.

Purpose of the Study:

  • To evaluate the safety and efficacy of the Hemopump, a novel intraarterial LVAD, in providing temporary circulatory support.
  • To assess the Hemopump's effectiveness in patients with various forms of severe heart failure.

Main Methods:

  • The Hemopump, a 7 mm transvalvular axial flow blood pump, was percutaneously inserted in 12 patients.
  • Indications included postcardiotomy shock, allograft rejection/failure, and acute myocardial infarction.

Related Experiment Videos

  • Device insertion was performed via femoral, ascending aortic, or abdominal aortic approaches.

    • Main Results:

    • The Hemopump provided effective circulatory support with cardiac index ranging from 1.14-2.98 L/min/m2 and pump flow of 3.0-3.6 L/min during the initial 12 hours.
    • Ten out of 12 patients were successfully weaned from the device, with support duration ranging from 26 to 139 hours.
    • No device-related infections or thromboembolic events occurred, and plasma-free hemoglobin remained acceptable.

    Conclusions:

    • The Hemopump serves as a safe and stable temporary circulatory support system.
    • Its percutaneous application minimizes complications associated with traditional LVAD implantation.
    • The device facilitates recovery in patients with severe left ventricular failure, with six patients surviving over 30 days post-removal.